非肌层浸润性膀胱癌的手术治疗研究进展
摘要
临床医生所关注的重点。传统经尿道膀胱肿瘤切除术TURBT是NMIBC的标准治疗方式但其在手术过程中可
能导致肿瘤碎片化及术后高复发率等遗留问题。为解决这一问题光动力诊断辅助TURBTPDD-TURBT和整
块切除术ERBT逐渐成为研究热点。PDD-TURBT通过增强对微小病变和原位癌CIS的识别提高了肿瘤
切除率减少了术后复发。而ERBT作为一种整块切除肿瘤的新技术避免了传统TURBT带来的肿瘤播散和碎片
化问题在改善术后病理评估和减少复发方面展现出巨大潜力。尽管PDD-TURBT和ERBT在成本和操作复杂性
上仍面临挑战但其在临床应用中的前景广阔有望为NMIBC的治疗提供更优选择。本综述将对TURBTPDDTURBT及ERBT的两种新近治疗方法展开阐述以期为NMIBC的治疗提供参考价值。
关键词
全文:
PDF参考
[1]Siegel RL, Giaquinto AN, Jemal A. Cancer statistics[J],
2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49.
[2]Bray F, Laversanne M, Sung H, Soerjomataram I,
et al. Global cancer statistics 2022: GLOBOCAN estimates
of incidence and mortality worldwide for 36 cancers in 185countries[J]. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.
[3]于昕冉，冯兵.基于CT影像组学预测非肌层浸
润性膀胱癌术后复发的临床价值[J].临床放射学杂志，
2024，43（05）：788-793.
[4]Fujii Y. Prediction models for progression of nonmuscle-invasive bladder cancer: A review[J]. Int J Urol. 2018
Mar;25(3):212-218.
[5]Bree KK, Shan Y, Hensley PJ, et al. Management,
Surveillance Patterns, and Costs Associated With Low-Grade
Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer
Among Older Adults, 2004-2013[J]. JAMA Netw Open.
2022;5(3):e223050.
[6]康海明，闫鹏宇，杨晓峰.光动力技术介导膀胱
癌精准诊疗的研究进展[J].现代泌尿外科杂志，2024，29
（08）：744-749.
[7]Kramer MW, Altieri V, Hurle R, et al. Current
Evidence of Transurethral En-bloc Resection of Nonmuscle
Invasive Bladder Cancer[J]. Eur Urol Focus. 2017;3(6):567-576.
[8]Mori K, D’Andrea D, Enikeev DV, et al. En bloc
resection for nonmuscle invasive bladder cancer: review of the
recent literature[J]. Curr Opin Urol. 2020;30(1):41-47.
[9]Maheshwari PN, Arora AM, Sane MS, et al. Safety,
feasibility, and quality of holmium laser en-bloc resection
of nonmuscle invasive bladder tumors - A single-center
experience[J]. Indian J Urol. 2020;36(2):106-111.
[10]Kausch I, Sommerauer M, Montorsi F, et al.
Photodynamic diagnosis in non-muscle-invasive bladder
cancer: a systematic review and cumulative analysis of
prospective studies[J]. Eur Urol. 2010;57(4):595-606.
[11]Babjuk M, Burger M, Capoun O, et al. European
Association of Urology Guidelines on Non-muscle-invasive
Bladder Cancer (Ta, T1, and Carcinoma in Situ)[J]. Eur Urol.
2022;81(1):75-94.
[12]Li M, Toniolo J, Nandurkar R, et al. Continuous
bladder irrigation after transurethral resection of non-muscle
invasive bladder cancer for prevention of tumour recurrence:
a systematic review[J]. ANZ J Surg. 2021;91(12):2592-2598.
[13]Ozer K, Horsanali MO, Gorgel SN, et al. Bladder
injury secondary to obturator reflex is more common
with plasmakinetic transurethral resection than monopolar
transurethral resection of bladder cancer[J]. Cent European J
Urol. 2015;68(3):284-288.
[14]McNicholas K, MacGregor MN, Gleadle JM. In
order for the light to shine so brightly, the darkness must be
present-why do cancers fluoresce with 5-aminolaevulinic
acid?[J]. Br J Cancer. 2019;121(8):631-639.
[15]顾佳毅，薄隽杰.表浅性膀胱癌的光动力诊断[J].
中国激光医学杂志，2009，18（05）：321-326.
[16]Nakamura Y, Ishikawa Y, Kobayashi M, et al.
Location-specific diagnostic efficiency of photodynamic
diagnosis-guided biopsy in bladder mapping biopsies. Int J
Urol. Published online August 2, 2024.
[17]Fukuhara H, Yamamoto S, Lai HW, et al.
Real-world experience with 5-aminolevulinic acid
for photodynamic diagnosis of bladder cancer (2nd
report): Reduced bladder recurrence after PDDTURBT[J]. Photodiagnosis Photodyn Ther. 2022;38:102757.
[18]Matsushita Y, Miyake M, Nishimura N, et
al. Comparative assessment of disease recurrence after
transurethral resection of non-muscle-invasive bladder
cancer with and without a photodynamic diagnosis using
5-aminolevulinic acid: a propensity score-matching
analysis[J]. Int J Clin Oncol. 2024;29(2):205-212.
[19]Miyake M, Nishimura N, Nakahama T, et al.
Differences in oncological benefits from second transurethral
resection between white-light initial surgery and
photodynamic diagnosis-guided initial surgery for primary
high-risk non-muscle invasive bladder cancer[J]. Int J Urol.
2024;31(8):876-885.
[20]Okabe Y, Fukuhara Y, Matsuoka W, et
al. Identification of risk factors associated with oral
5-aminolevulinic acid induced adverse events in
photodynamic diagnosis-transurethral resection of bladder
tumor[J]. Photodiagnosis Photodyn Ther. 2024;49:104291.
[21]Fukuhara H, Hagiwara Y, Oba K, et al. Realworld experience with 5-aminolevulinic acid for
photodynamic diagnosis of bladder cancer (3rd report):
Cost impact of transurethral resection of bladder tumor in
Japan[J]. Photodiagnosis Photodyn Ther. 2023;44:103758.
[22]Cumberbatch MGK, Foerster B, Catto JWF,
et al. Repeat Transurethral Resection in Non-muscleinvasive Bladder Cancer: A Systematic Review[J]. Eur Urol.2018;73(6):925-933.
[23]Herrmann TRW. En bloc resection of bladder
tumors (ERBT) revisited 12 years after reintroduction:
too good to be further ignored[J]. World J Urol.
2023;41(10):2577-2582.
[24]Diana P, Gallioli A, Fontana M, et al. Energy
source comparison in en-bloc resection of bladder tumors:
subanalysis of a single-center prospective randomized
study[J]. World J Urol. 2023;41(10):2591-2597.
[25]Yao Q, Niu H, Yang X, et al. A novel laser
resection approach: efficacy of rotatable bi-channel en bloc
resection of bladder tumor in a pilot in-vivo study[J]. Lasers
Med Sci. 2024;39(1):188.
[26]Enikeev D, Morozov A, Shpikina A, et al. A 10-
year renaissance of en bloc resection of bladder tumors
(ERBT): Are we approaching the peak or is it back to the
trough?[J]. World J Urol. 2023;41(10):2607-2615.
[27]D’Andrea D, Soria F, Hurle R, et al. En Bloc
Versus Conventional Resection of Primary Bladder Tumor
(eBLOC): A Prospective, Multicenter, Open-label,
Phase 3 Randomized Controlled Trial. Eur Urol Oncol.
2023;6(5):508-515.
[28]Wang, Chi-Wei et al. “Comparison of Pathological
Outcome and Recurrence Rate between En Bloc
Transurethral Resection of Bladder Tumor and Conventional
Transurethral Resection: A Meta-Analysis[J].”Cancers vol.
15,7 2055. 30 Mar. 2023, doi:10.3390/cancers15072055.
[29]Yanagisawa T, Matsukawa A, Iwatani K, et al.
En Bloc Resection Versus Conventional TURBT for
T1HG Bladder Cancer: A Propensity Score-Matched
Analysis[J]. Ann Surg Oncol. 2023;30(6):3820-3828.
[30]Yanagisawa T, Mori K, Motlagh RS, et al. En
Bloc Resection for Bladder Tumors: An Updated Systematic
Review and Meta-Analysis of Its Differential Effect on Safety,
Recurrence and Histopathology[J]. J Urol. 2022;207(4):754-
768.
[31]Miyake M, Nishimura N, Fujii T, et al.
Photodynamic Diagnosis-Assisted En Bloc Transurethral
Resection of Bladder Tumor for Nonmuscle Invasive
Bladder Cancer: Short-Term Oncologic and Functional
Outcomes[J]. J Endourol. 2021;35(3):319-327.
[32]Kannan D, Sekaran PG, Sankaran S, et al. The
Impact of En-bloc Transurethral Resection of Bladder
Tumour on Clinical, Pathological and Oncological Outcomes:
A Cohort Study[J]. Cureus. 2023;15(7):e42523.
[33]Yuen-Chun Teoh J, Cheng CH, Tsang CF, et al.
Transurethral En Bloc Resection Versus Standard Resection
of Bladder Tumour: A Randomised, Multicentre, Phase 3
Trial[J]. Eur Urol. 2024;86(2):103-111.
[34]Petov V, Timofeeva E, Sukhanov R, et al.
Prospective non-randomized comparison of transurethral laser
en bloc resection vs. conventional resection of bladder tumors
larger than 3 cm[J]. Minerva Urol Nephrol. 2024;76(4):436-
441.
Refbacks
- 当前没有refback。
